Advertisement

Thalidomide in Cutaneous Lupus Erythematosus

  • Yousuf Karim
  • Maria J. Cuadrado

Keywords

Systemic Lupus Erythematosus Lupus Nephritis Cutaneous Lupus Erythematosus Sensory Nerve Action Potential Localize Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aronson IK, Yu R, West DP, van den Broek H, Antel J (1984) Thalidomide induced peripheral neuropathy. Arch Dermatol 120:1466–1470CrossRefPubMedGoogle Scholar
  2. Atra E, Sato EI (1993) Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487–493Google Scholar
  3. Barnhill RL, Doll NJ, Millikan LE, Hastings RC (1984) Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 11:814–819PubMedGoogle Scholar
  4. Belmont HM, Buyon J, Giorno R, Abramson S (1994) Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37:376–383PubMedGoogle Scholar
  5. Clemmensen OJ, Olsen PZ, Andersen KE (1984) Thalidomide neurotoxicity. Arch Dermatol 120:338–341CrossRefPubMedGoogle Scholar
  6. Corral LG, Kaplan G (1999) Immunomodulationby thalidomide and thalidomide analogues. Ann Rheum Dis 58(Suppl I):I107–113PubMedGoogle Scholar
  7. D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitorof angiogenesis. Proc Natl Acad Sci USA 91:4082–4085PubMedGoogle Scholar
  8. de Iongh RU (1990) A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus. J Neuropathol Exp Neurol 49:564–581PubMedGoogle Scholar
  9. Dean GS, Tyrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251CrossRefPubMedGoogle Scholar
  10. Duong DJ, Spigel GT, Moxley TR 3rd, Gaspari AA (1999) American experiencewith low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135:1079–1087CrossRefPubMedGoogle Scholar
  11. Faure M, Thivolet J, Gaucherand M(1980) Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 269:275–280CrossRefPubMedGoogle Scholar
  12. Flageul B, Wallach D, Cavalier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L (2000) Thalidomide and thrombosis. Ann Dermatol Venereol127:171–174PubMedGoogle Scholar
  13. Frances C, El Khoury S, Gompler A, Becherel PA, Chosidow O, Piette JC (2002) Transient secondary amenorrhea in women treated by thalidomide. Eur J Dermatol 12:63–65PubMedGoogle Scholar
  14. Fullerton PM, O’Sullivan DJ (1968) Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatric 31:543–551Google Scholar
  15. Gad SM, Shannon EJ, Krotoski WA, Hastings RC (1985) Thalidomide induces imbalances in Tlymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 56:35–39PubMedGoogle Scholar
  16. Gardner-Medwin JM, Smith NJ, Powell RJ(1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828–832PubMedGoogle Scholar
  17. Geitz H, Handt S, Zwingenberger K(1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesionca scade. Immunopharmacology 31:213–221CrossRefPubMedGoogle Scholar
  18. Gompel A, Frances C, Piette JC, Blanc AS, Cordoliani F, Piette AM (1999) Ovarian failure with thalidomide treatment in complex aphthosis: commenton the concise communicationby Ordi et al. Arthritis Rheum 42:2259–2260CrossRefPubMedGoogle Scholar
  19. Gutiérrez-Rodriguez O, Starusta-Bacal P, Gutiérrez-Montes O (1989) Treatment of rheumatoid arthritis: the thalidomide experience. J Rheumatol 16:158–163PubMedGoogle Scholar
  20. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of Behcet’s syndrome. A randomised, double-blind, placebo controlled trial. Ann Intern Med 128:443–459PubMedGoogle Scholar
  21. Haslett PA, Corral LG, Albert M, Kaplan G(1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885–1892CrossRefPubMedGoogle Scholar
  22. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtando R, Avalos-Diaz E (1998) Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 7:154–158CrossRefPubMedGoogle Scholar
  23. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233–1237PubMedGoogle Scholar
  24. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on en dothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 135:678–686PubMedGoogle Scholar
  25. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382–22387CrossRefPubMedGoogle Scholar
  26. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 108:461–466PubMedGoogle Scholar
  27. Kohchiyama A, Oka D, Ueki H (1985) T-cell subsets in lesions of systemic and discoid lupus erythematosus. J Cutan Pathol 12:493–499PubMedGoogle Scholar
  28. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461–466CrossRefPubMedGoogle Scholar
  29. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN (2000) Experiencewith low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 39:218–222CrossRefPubMedGoogle Scholar
  30. Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, Julien J(1986) Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 9:837–844CrossRefPubMedGoogle Scholar
  31. Lee SH, Park SH, Min JK, Kim SI, Yoo WH, Hong YS, Park JH, Cho CS, Kim TG, Han H, Kim HY (1997) Decreased tumour necrosis factor-beta production in TNFB⋆2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 6:603–609PubMedGoogle Scholar
  32. McHugh SM, Rifkin IR, Deighton J Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW (1995) The immunosuppressive drug thalidomide induces T helper type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160–167PubMedGoogle Scholar
  33. Mellin GW, Katzenstein M(1962) The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med 23:1184–1190Google Scholar
  34. Mellin GW (1962) The saga of thalidomide (concluded). N Engl J Med. 267:1238–1244PubMedGoogle Scholar
  35. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor α productionby enhancingm RNA degradation. J Exp Med 177:1675–1680CrossRefPubMedGoogle Scholar
  36. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D (1999) Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 43:109–114PubMedGoogle Scholar
  37. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J (1994) Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130:66–69CrossRefPubMedGoogle Scholar
  38. Ordi-Ros J, Cortes F, Martinez N, Mauri M, de Torres I, Vilardell M(1998) Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 41:2273–2275CrossRefPubMedGoogle Scholar
  39. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M(2000) Thalidomide in the treatmentof cutaneous lupus refractory to conventional therapy. J Rheumatol 27:1429–1433PubMedGoogle Scholar
  40. Osman K, Comenzo R, Rajkumar SV (2001) Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951–1952CrossRefPubMedGoogle Scholar
  41. Passeron T, Lacour JP, Murr D, Ortonne JP (2001) Thalidomide-induced amenorrhea: two cases. Br J Dermatol 144:1262–1295CrossRefPubMedGoogle Scholar
  42. Powell RJ, Gardner-Medwin JM (1994) Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 70:901–904PubMedGoogle Scholar
  43. Randall T (1990) Thalidomide has 37-year history. JAMA 263:1474Google Scholar
  44. Rao DG, Kane NM, Oware A (2000) Thalidomide neuropathy: role of F-wave monitoring. Muscle Nerve 23:1301–1302CrossRefPubMedGoogle Scholar
  45. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomised, double-blind, placebo-controlled clinical trial. AIDS 10:1501–1507PubMedGoogle Scholar
  46. Rovelli A, Amigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, Vassallo E, Miniero R, Uderzo C (1998) The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation. Bone Marrow Transplant 21:577–581CrossRefPubMedGoogle Scholar
  47. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173:699–703CrossRefPubMedGoogle Scholar
  48. Sato EI, Assis LS, Lorenzi VP, Andrade LE (1998) Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 44:289–293CrossRefPubMedGoogle Scholar
  49. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand) 47:1105–1114Google Scholar
  50. Shannon EJ, Miranda RO, Morales MJ, Hastings RC (1981) Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 13:553–562PubMedGoogle Scholar
  51. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303–306Google Scholar
  52. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571CrossRefPubMedGoogle Scholar
  53. Stevens RJ, Andujar C, Edwards CJ, Ames PRJ, Barwick AR, Khamashta MA, Hughes GRV (1997) Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 36:353–359CrossRefPubMedGoogle Scholar
  54. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969–979CrossRefPubMedGoogle Scholar
  55. Vogelsang GB (1993) Acuteand chronic graft-versus-host disease. Curr Opin Oncol 5:276–281PubMedGoogle Scholar
  56. Walchner M, Messer G, Wierenga EA (1995) Reconstitution oftr anscription factorbinding to the conserved lymphokine element-o and downregulation of NF-kB activity after thalidomide treatment of systemic lupus erythematosus. Arch Dermatol Res 287:347Google Scholar
  57. Walchner M, Meurer M, Plewig G, Messer G (2000) Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 39:383–388CrossRefPubMedGoogle Scholar
  58. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586–1589CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • Yousuf Karim
  • Maria J. Cuadrado

There are no affiliations available

Personalised recommendations